This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002; 62: 4645–4655.
Yang Y, Ikezoe T, Nishioka C, Taguchi T, Koeffler HP, Taguchi H . ZD6474 induces growth arrest and apoptosis of GIST-T1 cells and this growth inhibition is enhanced by concomitant use of sunitinib. Cancer Sci 2006; 97: 1404–1409.
Staehler M, Rohrmann K, Haseke N, Stief CG, Siebels M . Targeted agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets 2005; 6: 835–846.
Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O'Farrell AM et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105: 986–993.
Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K et al. The anti-tumor effects of sunitinib (formerly SU11248) against a variety of human hematological malignancies: enhancement of growth inhibition via inhibition of mTOR signaling. Mol Cancer Ther 2006; 5: 2522–2530.
Acknowledgements
This work was supported in part by Kanae Foundation for the Promotion of the Medical Science, Public Trust of Haraguchi Memorial Cancer Research Fund, AstraZeneca Research Grant and the Fund for Academic Research from Kochi University. HPK is supported by NIH grants, as well as the Inger Fund and the Parker Hughes Trust.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nishioka, C., Ikezoe, T., Takeshita, A. et al. ZD6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel MEK inhibitor, AZD6244. Leukemia 21, 1308–1310 (2007). https://doi.org/10.1038/sj.leu.2404647
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404647
This article is cited by
-
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents
Investigational New Drugs (2012)
-
Inhibition of MEK/ERK signaling induces apoptosis of acute myelogenous leukemia cells via inhibition of eukaryotic initiation factor 4E-binding protein 1 and down-regulation of Mcl-1
Apoptosis (2010)
-
Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells
Leukemia (2008)
-
Inhibition of MEK/ERK signaling synergistically potentiates histone deacetylase inhibitor-induced growth arrest, apoptosis and acetylation of histone H3 on p21waf1 promoter in acute myelogenous leukemia cell
Leukemia (2008)